Prolog Ventures

Managing Directors Brian Clevinger and Ilya Nykin jointly drive investment decisions. Both hold PhDs and have operational science backgrounds — Clevinger in immunology, Nykin in molecular biology — which directly shapes the firm's ability to underwrite technical risk. The partnership structure is lean, with no publicly named junior partners or investment committee members beyond the two founders.

Prolog Ventures focuses exclusively on life sciences, food technology, and animal health. The firm has no known activity in consumer internet, enterprise SaaS, financial technology, or climate hardware. Its portfolio is deliberately narrow, reflecting a conviction that concentrated expertise in regulated, science-driven markets produces better risk-adjusted returns than generalist venture mandates can achieve.

The firm's St. Louis headquarters gives it proximity to Washington University in St. Louis and the Donald Danforth Plant Science Center, two research institutions that produce spinouts in biotech and ag-tech. Prolog also co-invests alongside regional partners like Cultivation Capital, creating a de facto syndication network that surfaces companies often missed by coastal venture firms scanning the Midwest.

Prolog Ventures operates as a direct investor, buying equity in early-stage operating companies rather than allocating to external venture funds. There is no public record of the firm acting as a limited partner in other managers' vehicles or building a fund-of-funds program. Capital is deployed exclusively toward building positions in individual startups.

The firm focuses on seed and early-stage companies, often entering when a company has a scientific proof of concept but lacks commercial validation. Checks typically go into pre-revenue biotech, diagnostics, ag-tech, and animal health firms that need bridge capital to reach clinical or field trials. Prolog does not historically pursue growth equity or late-stage pre-IPO rounds.